An update on nicotine as treatment for Parkinsons is reported in the new 2026 study findings reported below. This study concludes that nicotine provides welcome relief from tremors but also impairs robust cognitive functioning. It is contraindicative for Alzheimers.

Like pretty much everything in life, there are pluses and minuses to pretty much any treatment. Think of the choice as a two edged sword. Nicotine may offer relief from tremors but also result in cognitive impairment..

There is a natural alternative to nicotine which is derived from food which I think is worth consideration. It does not have the side effects of nicotine but provides similar benefits.

Anatabine is a minor natural alkaloid structurally similar to nicotine. It is found in low levels in plants of the Solanaceae family, including tobacco, tomatoes, potatoes and peppers. It has been studied for potential anti-inflammatory and neuro-protective properties.

Research Updates on Nicotine as Treatment for Parkinsons

Curr Neuropharmacol. 2026 Jun 12. Online ahead of print.

Nicotine Versus Non-Nicotine Constituents in Neurodegenerative Risk: Evidence from Multivariable Mendelian Randomization

Abstract

Background: Nicotine has complex neuropharmacological actions through nicotinic acetylcholine receptors, but its independent role in neurodegenerative diseases remains unclear because tobacco smoke contains many non-nicotine toxicants. This uncertainty limits the interpretation of nicotine- and nAChR-targeted therapeutic strategies, especially as electronic nicotine delivery sys-tems become more common. We used Mendelian randomization to genetically separate nicotine-related effects from smoking-related non-nicotine effects on major neurodegenerative diseases and related prodromal conditions.

Methods: We performed univariable two-sample Mendelian randomization (MR) and multivariable MR (MVMR) analyses. Summary-level exposure data for cigarettes per day (CPD) and the nicotine metabolite ratio (NMR) were analyzed against individual-level, smoking-stratified outcome data derived from 337,334 UK Biobank participants, to evaluate their respective causal effects across six neurodegenerative outcomes: Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), tremor, early cognitive impairment (EC), and other neurodegenerative diseases (OND).

Findings: MVMR analyses revealed that nicotine exposure was a causal risk factor for AD (ever smokers: OR=0.90, 95% CI 0.83-0.98; current smokers: OR=0.76, 95% CI 0.64-0.91). Nicotine exerted a causal protective effect against tremor (OR=1.24, 95% CI 1.03-1.49) and EC (OR=1.14, 95% CI 1.04-1.24) in current smokers. Non-nicotine tobacco constituents were identified as risk factors among former smokers for EC (OR=1.61, 95% CI 1.04-2.50).

Conclusions: Exposure to nicotine can increase the risks of AD, while conferring protective effects against tremor and EC. Furthermore, exposure to non-nicotine tobacco constituents acts as a risk factor for the incidence of EC.

******

Eur J Pharmacol. 2026 Feb 10:1014:178537. Anatabine: a substitute for the medicinal activity of nicotine

Abstract

Side effects and dependence limit the clinical application of nicotine. Anatabine, a structural analogue of nicotine, shares key molecular characteristics. Network-pharmacology and molecular-docking analyses demonstrate that both compounds target nicotinic acetylcholine receptors (nAChRs), with the pyridine ring serving as the primary interaction site.

This review synthesizes the pharmacology of anatabine, including anti-inflammatory, neuroprotective, and immunomodulatory activities, and underscores a therapeutic potential comparable to that of nicotine. Although anatabine shows affinity for ?7 nAChRs similar to that of nicotine, the role of this receptor in the effects of anatabine remains unclear. Nicotine exhibits substantially greater activation capability at ?4?2 nAChRs than anatabine (nicotine: EC50 = 0.4 ± 3.9 ?M; Imax = 17 ± 4 %; anatabine: EC50 = 8.4 ± 5.2 ?M; Imax = 4 ± 3 %), likely associated with differential electrostatic interactions between the two compounds with key residues (244, 385) within ?4?2 nAChRs. Consistently, anatabine shows a relatively low activity for ?4?2 nAChRs, which is closely related to nicotine dependence.

This may partly account for its lower addictive potential and milder central effects in disorders such as anxiety and Parkinson’s disease. Furthermore, its reported effectiveness in attenuating nicotine dependence and clinical use as an anti-arthritic dietary supplement to alleviate arthritis further supports its translational potential.

In summary, anatabine may represent a potentially safer alternative to nicotine with distinct pharmacological properties. This review comprehensively outlines its synthesis, quantification, and pharmacological activities, and provides perspectives for the subsequent research and development of anatabine.

Robert Rodgers PhD
Founder 2004
Parkinsons Recovery®